Cardiovascular Diseases

Cardiovascular diseases have the characteristics of high incidence, high disability, high mortality, high recurrence rate, and numerous complications, and these diseases are the main killers that seriously threaten human health. Among them, cardiovascular diseases such as coronary heart disease (including angina, myocardial infarction) and cerebrovascular diseases such as ischemic stroke (including cerebral thrombosis and cerebral embolism) all have a large number of unfulfilled clinical needs.

Product

Indication

Progress

More

PUK

STEMI

Marketed

PUK-B1440

APE

Phase III

PUK-B1448

APE

NDA

B1655

Hypercho- lesterolemia

Phase I

Oncology and Autoimmune Diseases

Tumor is one of the major diseases to endanger human health, and Tasly Biopharma focuses on the development of new drugs such as monoclonal antibodies, double antibodies and oncolytic virus. Among them, the product varieties under research include the recombinant fully-human EGFR-targeted monoclonal antibody SY101 for the treatment of advanced colorectal cancer, and the oncolytic virus product T601 for the treatment of advanced malignant solid tumors.

Product

Indication

Progress

More

SY101

Advanced colorectal cancer

Phase II

T601

Advanced malignant solid tumors of digestive tract

Phase I

B1451

RA、AMD

Pre- clinical

B1961

Advanced malignant solid tumors of digestive tract

Pre- clinical

B1962

Advanced malignant solid tumors of digestive tract

Pre- clinical

B2067

NMOSD

Pre- clinical

B2069

SLE、ALS

Pre- clinical

B2067-2

PNH、MG、 aHUS、NMOSD

Pre- clinical

Digestibility and Metabolism

With population aging, metabolic diseases such as diabetes, obesity, fatty liver and osteoporosis have become chronic diseases that seriously endanger people’s health. In response to unfulfilled clinical needs in the field of digestibility and metabolism, the strategic layout of Tasly Biopharma includes the following products:  B1344 for non-alcoholic steatohepatitis (NASH).

Product

Indication

Progress

More

B1344

NASH

Pre- clinical